Review of management issues in relapsed osteosarcoma.

abstract：INTRODUCTION:Neuroendocrine neoplasms of the lung (Lung NENs) encompass NE tumors (NETs), which are in turn split into typical and atypical carcinoids, and NE carcinomas (NECs), which group together small-cell carcinoma and large-cell NE carcinoma. This classification is the current basis for orienting the daily practi...

journal_title：Expert review of anticancer therapy

authors： Metovic J,Barella M,Harari S,Pattini L,Albini A,Sonzogni A,Veronesi G,Papotti M,Pelosi G

更新日期：2020-12-24 00:00:00

abstract：:Androgen receptor (AR) signaling is necessary for the development of prostate cancer. Androgen-deprivation therapy (ADT) for prostate cancer was described over 50 years ago and ADT remains the mainstay of systemic therapy. AR signaling remains intact as the disease evolves to castration-resistant prostate cancer (CRPC...

journal_title：Expert review of anticancer therapy

authors： Taplin ME

更新日期：2008-09-01 00:00:00

abstract：:Knowledge of the prognostic role of biomarkers in colorectal cancer is limited and the routine determination for clinical practice is not warranted. However, for some of these markers, data are promising enough for further evaluation. This review addresses a comprehensive analysis of prognostic biomarkers in colorecta...

journal_title：Expert review of anticancer therapy

authors： Graziano F,Catalano V,Baldelli AM,Cascinu S

更新日期：2001-08-01 00:00:00

abstract：:Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells,...

journal_title：Expert review of anticancer therapy

authors： Sigal DS,Saven A

更新日期：2008-04-01 00:00:00

abstract：:Proteasome inhibition has been shown to be an effective strategy for the treatment of multiple myeloma, as demonstrated by the clinical activity of the first-in-class agent bortezomib. Recently, the second-generation proteasome inhibitor carfilzomib has been approved in the USA in the relapsed and refractory setting, ...

journal_title：Expert review of anticancer therapy

authors： McBride A,Ryan PY

更新日期：2013-03-01 00:00:00

abstract：:In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological pattern...

journal_title：Expert review of anticancer therapy

authors： Franceschi E,Agati R,Brandes AA

更新日期：2011-11-01 00:00:00

abstract：:Raltitrexed is a cytotoxic agent, rationally designed to inhibit a specific molecular target, thymidylate synthase. In contrast to other agents, raltitrexed inhibits thymidylate synthase directly and specifically in a mixed, noncompetitive manner, which may lead to an improved toxicity profile. After promising Phase I...

journal_title：Expert review of anticancer therapy

authors： Surmont VF,van Meerbeeck JP

更新日期：2011-10-01 00:00:00

abstract：:Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the t...

journal_title：Expert review of anticancer therapy

authors： Kose MF,Meydanli MM,Tulunay G

更新日期：2006-03-01 00:00:00

abstract：:The association between venous thromboembolism (VTE) and malignancy was first recognized more than 135 years ago. Since then, a markedly increased incidence of VTE has been found in patients with malignant disease. Numerous clinical studies have demonstrated that malignancy or its treatment are major risk factors for ...

journal_title：Expert review of anticancer therapy

authors： Gao S,Escalante C

更新日期：2004-04-01 00:00:00

abstract：:Treatment options for patients have increased over the last few years, especially with the availability of novel agents for routine care and within clinical trials. Owing to the promising activity seen with lenalidomide in the relapsed/refractory setting, its use has now expanded to induction and maintenance therapy. ...

journal_title：Expert review of anticancer therapy

authors： Sirohi B,Powles R

更新日期：2009-11-01 00:00:00

abstract：:Combined therapy with temozolomide and radiotherapy is a standard treatment and improves the survival for patients with newly diagnosed glioblastoma. However, the prognosis remains poor, with a median survival time of 12-15 months. Currently, several clinical trials of dose-dense temozolomide regimen or molecular-targ...

journal_title：Expert review of anticancer therapy

authors： Shirai K,Chakravarti A

更新日期：2011-12-01 00:00:00

abstract：:Dietary factors and other naturally occurring substances may emerge as potent therapeutic or preventative agents in the battle against prostate cancer. Much of the current support for these agents is epidemiologically based, but new prospective studies are now underway which may support their use in conventional medic...

journal_title：Expert review of anticancer therapy

authors： Ward JF,Blute ML

更新日期：2003-04-01 00:00:00

abstract：:Anemia in cancer patients is frequent but often under-recognized and under-treated. This may be related to misconceptions about the impact of anemia on cancer patients and ill-defined guidelines for treatment, as well as the inadequacies of current therapy. Darbepoetin alfa, a novel erythropoiesis-stimulating protein ...

journal_title：Expert review of anticancer therapy

authors： Pirker R,Smith R

更新日期：2002-08-01 00:00:00

abstract：INTRODUCTION:Dysfunction of the immune system is a hallmark of cancer. Through increased understanding of the complex interactions between immunity and cancer, immunotherapy has emerged as a treatment modality for different types of cancer. Promising activity with immunotherapy has been reported in numerous malignancie...

journal_title：Expert review of anticancer therapy

authors： Zeidan AM,Komrokji RS,Brunner AM

更新日期：2021-01-19 00:00:00

abstract：:Intensity-modulated radiation therapy (IMRT) represents a powerful advance in the planning and delivery of radiation therapy owing to its ability to deliver highly conformal treatment doses while sparing normal tissues. Dosimetric studies have shown the feasibility and theoretical benefit of treating with IMRT over 3D...

journal_title：Expert review of anticancer therapy

authors： Bockbrader M,Kim E

更新日期：2009-05-01 00:00:00

abstract：:Metastasis contributes to over 90% of cancer-related deaths. Many types of cancer metastasize via the bloodstream, where circulating tumor cells (CTCs) originating from the primary tumor can undergo selectin-mediated adhesion with the blood vessel wall and subsequently transmigrate to anatomically distant organs. In a...

journal_title：Expert review of anticancer therapy

authors： Mitchell MJ,King MR

更新日期：2014-06-01 00:00:00

abstract：:Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...

journal_title：Expert review of anticancer therapy

authors： Kortmann RD

更新日期：2014-01-01 00:00:00

abstract：:There is increasing interest in the use of prognostic markers that may predict survival and guide management in patients diagnosed with the early stages of chronic lymphocytic leukemia (CLL). Currently, the most important traditional prognostic factors include clinical staging, lymphocyte doubling time and β2-microglo...

journal_title：Expert review of anticancer therapy

authors： Bazargan A,Tam CS,Keating MJ

更新日期：2012-03-01 00:00:00

abstract：:Ovarian cancer frequently presents late, when chances for long-term survival are poor. The increased survival advantage for patients diagnosed with early-stage ovarian cancer suggests that screening to detect early-stage disease might have an impact on disease mortality. Attempts are being made to develop effective sc...

journal_title：Expert review of anticancer therapy

authors： Lewis S,Menon U

更新日期：2003-02-01 00:00:00

abstract：INTRODUCTION:Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast c...

journal_title：Expert review of anticancer therapy

authors： Griguolo G,Dieci MV,Guarneri V,Conte P

更新日期：2018-06-01 00:00:00

abstract：:Pulmonary complications of antineoplastic therapy are common and are an important cause of respiratory morbidity. The pulmonary toxicity should be taken into account in every patient with respiratory problems who is or has been treated with antineoplastic agents. The diagnosis of drug-induced pulmonary toxicity is com...

journal_title：Expert review of anticancer therapy

authors： Sadowska AM,Specenier P,Germonpre P,Peeters M

更新日期：2013-08-01 00:00:00

abstract：:Rapid malignant proliferation, prior to effective tumor neoangiogenesis, creates a microenvironment around solid cancers, which is predominantly hypoxic and characterized by a high interstitial fluid pressure. Presumably as an adaptive response, tumor cells favor metabolic activity with apparently inefficient energy o...

journal_title：Expert review of anticancer therapy

authors： Abaza M,Luqmani YA

更新日期：2013-10-01 00:00:00

abstract：INTRODUCTION:In the last decade tyrosine kinase inhibitors (TKIs) have been employed for a wide range of hematological and solid tumors and today they represent a valid therapeutic option for different neoplasms. Among them, both sorafenib and lenvatinib were approved for the treatment of radioactive iodine (RAI) refra...

journal_title：Expert review of anticancer therapy

authors： Felicetti F,Nervo A,Piovesan A,Berardelli R,Marchisio F,Gallo M,Arvat E

更新日期：2017-12-01 00:00:00

abstract：:Introduction: Pembrolizumab is an immune checkpoint inhibitor with high specificity for binding to the programmed cell death 1 (PD-1) receptor. It has been approved by the FDA in patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express the programmed ...

journal_title：Expert review of anticancer therapy

authors： De Felice F,Giudice E,Bolomini G,Distefano MG,Scambia G,Fagotti A,Marchetti C

更新日期：2020-11-26 00:00:00

abstract：:Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/o...

journal_title：Expert review of anticancer therapy

authors： Jimeno A,Carducci M

更新日期：2005-06-01 00:00:00

abstract：:Many solid tumors, including breast and prostate cancer, metastasize to bone, thereby putting patients at high risk for developing skeletal complications including pathologic fracture, spinal cord compression and debilitating bone pain. Patients often live for many years after developing bone metastasis, a fact that h...

journal_title：Expert review of anticancer therapy

authors： Gulley J,Dahut WL

更新日期：2005-04-01 00:00:00

abstract：:Bladder cancer is a significant cause of morbidity and mortality. Promising results with organ preservation strategies using multimodality treatment over the last decade offers an option for bladder preservation in a significant proportion of patients who currently undergo cystectomy. The primary goal of the bladder-s...

journal_title：Expert review of anticancer therapy

authors： Hussain SA,James ND

更新日期：2002-12-01 00:00:00

abstract：:Cancer-related anorexia/cachexia syndrome is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumor-derived catabolic factors, decreased food intake and probably additional unknown factors all play different roles. This review examines the...

journal_title：Expert review of anticancer therapy

authors： Mantovani G,Macciò A,Madeddu C,Massa E

更新日期：2003-06-01 00:00:00

abstract：:A recent population-based study on 2000 adult patients with Burkitt lymphoma presented a novel score that takes into account age, race and clinical stage to prognosticate survival. The outcome of patients with Burkitt lymphoma has improved in the last decade, likely due to intensive chemotherapy regimens and anti-CD20...

journal_title：Expert review of anticancer therapy

authors： Castillo JJ,Nadeem O

更新日期：2014-02-01 00:00:00

abstract：:Positron emission tomography (PET) using [(18)F]-2-deoxy-2-fluoro-d-glucose (FDG) has emerged as a valuable diagnostic modality in patients with non-small cell lung cancer (NSCLC). Data in the literature show that the addition of FDG-PET definitely alters clinical management in patients with potentially resectable NSC...

journal_title：Expert review of anticancer therapy

authors： Oyen WJ,Bussink J,Verhagen AF,Corstens FH,Bootsma GP

更新日期：2004-08-01 00:00:00